Hexarelin Side Effects

Known side effects

The following side effects have been reported in research studies and user reports for Hexarelin:

• Fastest desensitization of any GHRP: GH response attenuation begins within 2 to 4 weeks of daily use and progresses with continued administration, limiting effective cycle length to 4 to 8 weeks. Post-cycle receptor recovery typically requires 4 weeks of abstinence before sensitivity is restored (PMID: 7671860)
• Significant cortisol elevation: Hexarelin produces the most pronounced cortisol increases of any GHRP class member at equivalent doses, through direct GHS-R1a activation in adrenocortical cells. This cortisol burden is a primary reason to prefer ipamorelin or GHRP-2 for longer protocols where cumulative cortisol exposure is a concern
• Significant prolactin elevation: Prolactin rises substantially with each hexarelin injection through GHS-R1a activation on pituitary lactotrophs. Chronic prolactin elevation increases gynecomastia risk in men and may cause menstrual irregularities in women with sustained high-dose protocols
• Water retention: High-amplitude GH pulses drive more pronounced fluid retention than lower-potency GHRPs, with associated bloating and peripheral edema that can be cosmetically significant in the first few weeks of use
• Appetite stimulation: Moderate and predictable, beginning 15 to 30 minutes post-injection. More manageable than GHRP-6 but more noticeable than ipamorelin. Timing injections before meals is the standard mitigation approach
• Injection site reactions: Localized redness and mild swelling at subcutaneous injection sites, similar to other GHRPs. Rotating injection sites across the abdomen reduces cumulative site irritation
• Risk of diminishing returns with early cycle extension: Users who extend hexarelin cycles beyond 8 weeks typically report progressively weaker GH responses, indicating receptor downregulation that will require a full break to reverse rather than dose escalation

Severity and frequency

Limited clinical data is available for Hexarelin. Side effect frequency and severity are based on available research and anecdotal reports. More data is needed for definitive safety profiles.

When to seek medical attention

Contact your healthcare provider immediately if you experience:

• Severe or persistent symptoms that do not improve
• Signs of an allergic reaction (rash, swelling, difficulty breathing)
• Severe abdominal pain
• Changes in vision or neurological symptoms
• Any symptom that concerns you

Risk factors

Side effect risk may be higher in certain populations. Discuss your complete medical history with your doctor, including:

• Pre-existing medical conditions
• Current medications (drug interactions)
• Pregnancy or plans to become pregnant
• History of allergic reactions to peptides or similar compounds
• Note: Hexarelin is a research compound without established human safety data from FDA-approved clinical trials

Research references

• Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during somatostatin infusion and after exogenous somatostatin and GHRH in humans — Journal of Clinical Endocrinology and Metabolism (1994) [PubMed]
• Comparison of growth hormone (GH)-releasing peptides: stimulation of GH release from perifused rat anterior pituitaries by GHRP-1, GHRP-2, GHRP-6, hexarelin, and MK-0677 — Endocrinology (1997) [PubMed]
• Hexarelin peptide: a growth hormone-releasing peptide with cardioprotective activity — Proceedings of the National Academy of Sciences (2000) [PubMed]